Exact Mass: 385.26168000000007
Exact Mass Matches: 385.26168000000007
Found 256 metabolites which its exact mass value is equals to given mass value 385.26168000000007,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Buspirone
Buspirone is only found in individuals that have used or taken this drug. It is an anxiolytic agent and a serotonin receptor agonist belonging to the azaspirodecanedione class of compounds. Its structure is unrelated to those of the benzodiazepines, but it has an efficacy comparable to diazepam. [PubChem]Buspirone binds to 5-HT type 1A serotonin receptors on presynaptic neurons in the dorsal raphe and on postsynaptic neurons in the hippocampus, thus inhibiting the firing rate of 5-HT-containing neurons in the dorsal raphe. Buspirone also binds at dopamine type 2 (DA2) receptors, blocking presynaptic dopamine receptors. Buspirone increases firing in the locus ceruleus, an area of brain where norepinephrine cell bodies are found in high concentration. The net result of buspirone actions is that serotonergic activity is suppressed while noradrenergic and dopaminergic cell firing is enhanced. CONFIDENCE standard compound; INTERNAL_ID 520; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 6951; ORIGINAL_PRECURSOR_SCAN_NO 6950 CONFIDENCE standard compound; INTERNAL_ID 520; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 6947; ORIGINAL_PRECURSOR_SCAN_NO 6945 CONFIDENCE standard compound; INTERNAL_ID 520; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 6914; ORIGINAL_PRECURSOR_SCAN_NO 6912 CONFIDENCE standard compound; INTERNAL_ID 520; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 6879; ORIGINAL_PRECURSOR_SCAN_NO 6877 CONFIDENCE standard compound; INTERNAL_ID 520; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 6955; ORIGINAL_PRECURSOR_SCAN_NO 6953 CONFIDENCE standard compound; INTERNAL_ID 520; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 6922; ORIGINAL_PRECURSOR_SCAN_NO 6920 D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014151 - Anti-Anxiety Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents N - Nervous system > N05 - Psycholeptics > N05B - Anxiolytics > N05BE - Azaspirodecanedione derivatives D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D017366 - Serotonin Receptor Agonists D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants C78272 - Agent Affecting Nervous System > C28197 - Antianxiety Agent Buspirone is an orally active 5-HT1A receptor agonist, and a dopamine D2 autoreceptorsant antagonist. Buspirone is an anxiolytic agent, and can be used for the generalized anxiety disorder research[1].
Actinonin
C19H35N3O5 (385.25765800000005)
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents Actinonin ((-)-Actinonin) is a naturally occurring antibacterial agent produced by Actinomyces. Actinonin inhibits aminopeptidase M, aminopeptidase N and leucine aminopeptidase. Actinonin is a potent reversible peptide deformylase (PDF) inhibitor with a Ki of 0.28 nM. Actinonin also inhibits MMP-1, MMP-3, MMP-8, MMP-9, and hmeprin α with Ki values of 300 nM, 1,700 nM, 190 nM, 330 nM, and 20 nM, respectively. Actinonin is an apoptosis inducer. Actinonin has antiproliferative and antitumor activities[1][2][3][4][5].
3-Hydroxy-cis-5-tetradecenoylcarnitine
3-Hydroxy-cis-5-tetradecenoylcarnitine is an acylcarnitine. More specifically, it is an (5Z)-3-hydroxytetradec-5-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-Hydroxy-cis-5-tetradecenoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 3-hydroxy-cis-5-tetradecenoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. In particular 3-hydroxy-cis-5-tetradecenoylcarnitine is elevated in the blood or plasma of individuals with psoriasis (PMID: 33391503) and coronary artery disease (PMID: 20173117). 3-Hydroxy-cis-5-tetradecenoylcarnitine is elevated in the urine of individuals with obstructive sleep apnea (https://doi.org/10.1007/s11306-017-1216-9) and mitochondrial trifunctional protein deficiency (PMID: 19880769). Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
Tridec-8-enedioylcarnitine
C20H35NO6 (385.24642500000004)
Tridec-8-enedioylcarnitine is an acylcarnitine. More specifically, it is an tridec-8-enedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Tridec-8-enedioylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine Tridec-8-enedioylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
Tridec-10-enedioylcarnitine
C20H35NO6 (385.24642500000004)
Tridec-10-enedioylcarnitine is an acylcarnitine. More specifically, it is an tridec-10-enedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Tridec-10-enedioylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine Tridec-10-enedioylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
Tridec-11-enedioylcarnitine
C20H35NO6 (385.24642500000004)
Tridec-11-enedioylcarnitine is an acylcarnitine. More specifically, it is an tridec-11-enedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Tridec-11-enedioylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine Tridec-11-enedioylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(6E)-Tridec-6-enedioylcarnitine
C20H35NO6 (385.24642500000004)
(6E)-Tridec-6-enedioylcarnitine is an acylcarnitine. More specifically, it is an (6E)-tridec-6-enedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (6E)-Tridec-6-enedioylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (6E)-Tridec-6-enedioylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(9E)-Tridec-9-enedioylcarnitine
C20H35NO6 (385.24642500000004)
(9E)-Tridec-9-enedioylcarnitine is an acylcarnitine. More specifically, it is an (9E)-tridec-9-enedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (9E)-Tridec-9-enedioylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (9E)-Tridec-9-enedioylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(6Z)-9-Hydroxytetradec-6-enoylcarnitine
(6Z)-9-Hydroxytetradec-6-enoylcarnitine is an acylcarnitine. More specifically, it is an (6Z)-9-hydroxytetradec-6-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (6Z)-9-Hydroxytetradec-6-enoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (6Z)-9-Hydroxytetradec-6-enoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. In particular (6Z)-9-Hydroxytetradec-6-enoylcarnitine is elevated in the blood or plasma of individuals with psoriasis (PMID: 33391503) and coronary artery disease (PMID: 20173117). (6Z)-9-Hydroxytetradec-6-enoylcarnitine is elevated in the urine of individuals with obstructive sleep apnea (https://doi.org/10.1007/s11306-017-1216-9) and mitochondrial trifunctional protein deficiency (PMID: 19880769). Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(12E)-10-Hydroxytetradec-12-enoylcarnitine
(12E)-10-Hydroxytetradec-12-enoylcarnitine is an acylcarnitine. More specifically, it is an (12E)-10-hydroxytetradec-12-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (12E)-10-Hydroxytetradec-12-enoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (12E)-10-Hydroxytetradec-12-enoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. In particular (12E)-10-Hydroxytetradec-12-enoylcarnitine is elevated in the blood or plasma of individuals with psoriasis (PMID: 33391503) and coronary artery disease (PMID: 20173117). (12E)-10-Hydroxytetradec-12-enoylcarnitine is elevated in the urine of individuals with obstructive sleep apnea (https://doi.org/10.1007/s11306-017-1216-9) and mitochondrial trifunctional protein deficiency (PMID: 19880769). Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(3Z)-5-Hydroxytetradec-3-enoylcarnitine
(3Z)-5-Hydroxytetradec-3-enoylcarnitine is an acylcarnitine. More specifically, it is an (3Z)-5-hydroxytetradec-3-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (3Z)-5-Hydroxytetradec-3-enoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (3Z)-5-Hydroxytetradec-3-enoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. In particular (3Z)-5-Hydroxytetradec-3-enoylcarnitine is elevated in the blood or plasma of individuals with psoriasis (PMID: 33391503) and coronary artery disease (PMID: 20173117). (3Z)-5-Hydroxytetradec-3-enoylcarnitine is elevated in the urine of individuals with obstructive sleep apnea (https://doi.org/10.1007/s11306-017-1216-9) and mitochondrial trifunctional protein deficiency (PMID: 19880769). Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(5E)-8-Hydroxytetradec-5-enoylcarnitine
(5E)-8-Hydroxytetradec-5-enoylcarnitine is an acylcarnitine. More specifically, it is an (5E)-8-hydroxytetradec-5-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (5E)-8-Hydroxytetradec-5-enoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (5E)-8-Hydroxytetradec-5-enoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. In particular (5E)-8-Hydroxytetradec-5-enoylcarnitine is elevated in the blood or plasma of individuals with psoriasis (PMID: 33391503) and coronary artery disease (PMID: 20173117). (5E)-8-Hydroxytetradec-5-enoylcarnitine is elevated in the urine of individuals with obstructive sleep apnea (https://doi.org/10.1007/s11306-017-1216-9) and mitochondrial trifunctional protein deficiency (PMID: 19880769). Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(2E)-4-Hydroxytetradec-2-enoylcarnitine
(2E)-4-Hydroxytetradec-2-enoylcarnitine is an acylcarnitine. More specifically, it is an (2E)-4-hydroxytetradec-2-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (2E)-4-Hydroxytetradec-2-enoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (2E)-4-Hydroxytetradec-2-enoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. In particular (2E)-4-Hydroxytetradec-2-enoylcarnitine is elevated in the blood or plasma of individuals with psoriasis (PMID: 33391503) and coronary artery disease (PMID: 20173117). (2E)-4-Hydroxytetradec-2-enoylcarnitine is elevated in the urine of individuals with obstructive sleep apnea (https://doi.org/10.1007/s11306-017-1216-9) and mitochondrial trifunctional protein deficiency (PMID: 19880769). Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
3-oxotetradecanoylcarnitine
3-oxotetradecanoylcarnitine is an acylcarnitine. More specifically, it is an 3-oxotetradecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-oxotetradecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 3-oxotetradecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
N-Palmitoyl Glutamic acid
N-palmitoyl glutamic acid, also known as N-palmitoyl glutamate belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is a Palmitic acid amide of Glutamic acid. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Palmitoyl Glutamic acid is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Palmitoyl Glutamic acid is therefore classified as a long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.
N-Oleoyl Cysteine
C21H39NO3S (385.26505040000006)
N-oleoyl cysteine belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is an Oleic acid amide of Cysteine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Oleoyl Cysteine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Oleoyl Cysteine is therefore classified as a long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.
N-Docosahexaenoyl Glycine
C24H35NO3 (385.26168000000007)
N-docosahexaenoyl glycine belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is a Docosahexaenoyl amide of Glycine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Docosahexaenoyl Glycine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Docosahexaenoyl Glycine is therefore classified as a very long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.
Actinonin
C19H35N3O5 (385.25765800000005)
8-(2-[4-(2-Methoxyphenyl)-1-piperazinyl]ethyl)-8-azaspiro[4.5]decane-7,9-dione
C22H31N3O3 (385.23652960000004)
D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists
Stachyflin
C23H31NO4 (385.22529660000004)
Temiverine
C24H35NO3 (385.26168000000007)
2-amino-3-hydroxy-2-(1-hydroxy-12-oxo-4-octadecenyl)propionic acid
N-Docosa-4,7,10,13,16,19-hexaenoylglycine
C24H35NO3 (385.26168000000007)
4,5-dihydroguineensine|piperchabamide D
C24H35NO3 (385.26168000000007)
1-Methoxy-3-[3,5-dimethyl-6-(1-methylpropyl)tetrahydro-2H-pyran-2-yl]-4-hydroxy-5-phenylpyridine-2(1H)-one
C23H31NO4 (385.22529660000004)
(5S)-(Z)-epicoccarine A|epicoccarine A
C23H31NO4 (385.22529660000004)
methyl 4-[(E)-2-acetyl-4-oxoundec-1-enyl]-6-[(E)-prop-1-enyl]-nicotinate|monascopyridine F|Monasnicotinate C
C23H31NO4 (385.22529660000004)
4,6-dihydroxy-5-[(2E,6E)-(3,7,11-trimethyl-2,6,10-dodecatrien-1-yl)oxy]-2,3-dihydro-1H-isoindol-1-one|emeriphenolicin F
C23H31NO4 (385.22529660000004)
9,10-epoxycalycine A|caldaphnidine I
C23H31NO4 (385.22529660000004)
(3R*,4S*,5S*,6S*,8R*,10R*)-3-[1,2,4a,5,6,7,8,8a-octahydro-3,6,8-trimethyl-2-[(E)-1-methyl-1-propenyl]-1-naphthalenyl]carbonyl-1,5-dihydro-5-methoxy-5-methyl-2H-pyrrol-2-one|ascosalipyrrolidinone B
C24H35NO3 (385.26168000000007)
buspirone
D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014151 - Anti-Anxiety Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents N - Nervous system > N05 - Psycholeptics > N05B - Anxiolytics > N05BE - Azaspirodecanedione derivatives D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D017366 - Serotonin Receptor Agonists D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants C78272 - Agent Affecting Nervous System > C28197 - Antianxiety Agent Buspirone is an orally active 5-HT1A receptor agonist, and a dopamine D2 autoreceptorsant antagonist. Buspirone is an anxiolytic agent, and can be used for the generalized anxiety disorder research[1].
MLS002153199-01!Actinonin13434-13-4
C19H35N3O5 (385.25765800000005)
C23H31NO4_Spiro[2H-furo[2,3-e]isoindole-2,1(2H)-naphthalen]-6(3H)-one, 3,4,4a,5,6,7,7,8,8,8a-decahydro-4,6-dihydroxy-2,5,5,8a-tetramethyl-, (2R,2R,6R,8aS)
C23H31NO4 (385.22529660000004)
(3R,7R,8R,8aS)-3,4-dihydroxy-4,4,7,8a-tetramethylspiro[2,3,4a,5,6,7-hexahydro-1H-naphthalene-8,2-7,8-dihydro-3H-furo[2,3-e]isoindole]-6-one
C23H31NO4 (385.22529660000004)
Ala Ala Lys Pro
Ala Ala Pro Lys
Ala Lys Ala Pro
Ala Lys Pro Ala
Ala Pro Ala Lys
Ala Pro Lys Ala
Lys Ala Ala Pro
Lys Ala Pro Ala
Lys Pro Ala Ala
Pro Ala Ala Lys
Pro Ala Lys Ala
Pro Lys Ala Ala
Docosahexaenoyl Glycine
C24H35NO3 (385.26168000000007)
(4S,5S)-1,3-DIMETHYL-4,5-DIPHENYL-2-[(R)-1-BENZYL-2-HYDROXYETHYLIMINO]IMIDAZOLIDINE
C25H27N3O (385.21540120000003)
Vinyl tris(methylisobutylketoximino) silane
C19H39N3O3Si (385.27605439999996)
4-[(2-Butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-[1,1-Biphenyl]-2-carbonitrile
C25H27N3O (385.21540120000003)
Methylsamidorphan
C78276 - Agent Affecting Digestive System or Metabolism > C29697 - Laxative C78272 - Agent Affecting Nervous System > C681 - Opiate Antagonist
Temiverine
C24H35NO3 (385.26168000000007)
D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists C78272 - Agent Affecting Nervous System > C29698 - Antispasmodic Agent D002317 - Cardiovascular Agents > D002121 - Calcium Channel Blockers D000077264 - Calcium-Regulating Hormones and Agents D049990 - Membrane Transport Modulators
3beta-(1-Pyrrolidinyl)-5alpha-pregnane-11,20-dione
(S)-N-(4-Carbamimidoylbenzyl)-1-(2-(Cyclohexylamino)ethanoyl)pyrrolidine-2-Carboxamide
N-[(3S)-3-hydroxy-4-oxo-4-(propylamino)butanoyl]-L-isoleucyl-L-proline
3-Hydroxy-16-methoxy-2,3-dihydrotabersoninium
An indole alkaloid cation that is the conjugate acid of 3-hydroxy-16-methoxy-2,3-dihydrotabersonine, obtained by protonation of the tertiary amino function; major species at pH 7.3.
12alpha-Hydroxy-3-oxochola-4,6-dien-24-oate
C24H33O4- (385.23787180000005)
Glycine, N-(1-oxo-4,7,10,13,16,19-docosahexaenyl)-(9CI)
C24H35NO3 (385.26168000000007)
(E)-3,17-dihydroxy-4-oxo-3-[(trimethylazaniumyl)methyl]heptadec-5-enoate
1-[2-(Diethylamino)ethyl]-7,7-dimethyl-2-(4-methylphenyl)-5,8-dihydropyrano[4,3-d]pyrimidine-4-thione
1-ethyl-2-[3-(1-ethyl-3,3-dimethyl-1,3-dihydro-2H-indol-2-ylidene)prop-1-en-1-yl]-3,3-dimethyl-3H-indolium
Pordamacrine B, (rel)-
C23H31NO4 (385.22529660000004)
A natural product found in Daphniphyllum macropodum.
8-[(1-Cyclohexyl-5-tetrazolyl)methyl]-3-(4-fluorophenyl)-8-azabicyclo[3.2.1]octan-3-ol
N-[3-(3,5-dimethylpiperidin-1-yl)propyl]-2-[(1-methyl-2-oxo-1,2-dihydroquinolin-4-yl)oxy]acetamide
C22H31N3O3 (385.23652960000004)
N-[3-(2-ethylpiperidin-1-yl)propyl]-2-[(1-methyl-2-oxo-1,2-dihydroquinolin-4-yl)oxy]acetamide
C22H31N3O3 (385.23652960000004)
N-[[3-(3-methylphenyl)-1-(4-methylphenyl)-4-pyrazolyl]methyl]-3-(1-pyrazolyl)-1-propanamine
1-[3-[2-(Dimethylamino)ethylamino]-3-oxopropyl]-2-methyl-5-(4-methylphenyl)-3-pyrrolecarboxylic acid ethyl ester
C22H31N3O3 (385.23652960000004)
[(2S,3S,4S)-1-(4-ethyl-1,3-thiazol-2-yl)-4-[(propan-2-ylamino)methyl]-3-[4-[(E)-prop-1-enyl]phenyl]azetidin-2-yl]methanol
4-[4-[(1S,5R)-3-[cyclohexyl(oxo)methyl]-3,6-diazabicyclo[3.1.1]heptan-7-yl]phenyl]benzonitrile
C25H27N3O (385.21540120000003)
5-(3-Cyclohexyl-1-pyrrolidinyl)-6-phenyl-3-(2-pyridinyl)-1,2,4-triazine
[(2R,3R,4R)-1-(4-ethyl-1,3-thiazol-2-yl)-4-[(propan-2-ylamino)methyl]-3-[4-[(E)-prop-1-enyl]phenyl]azetidin-2-yl]methanol
1-[[(2R,3R,4S)-1-(cyclopropanecarbonyl)-4-(hydroxymethyl)-3-[4-[(E)-prop-1-enyl]phenyl]azetidin-2-yl]methyl]-3-propan-2-ylurea
C22H31N3O3 (385.23652960000004)
1-[[(2S,3S,4R)-1-(cyclopropanecarbonyl)-4-(hydroxymethyl)-3-[4-[(E)-prop-1-enyl]phenyl]azetidin-2-yl]methyl]-3-propan-2-ylurea
C22H31N3O3 (385.23652960000004)
(2S,3S,4R)-2-(acetamidomethyl)-3-[4-(1-cyclopentenyl)phenyl]-4-(hydroxymethyl)-N-propyl-1-azetidinecarboxamide
C22H31N3O3 (385.23652960000004)
(2R,3S,4S)-3-[4-(1-cyclohexenyl)phenyl]-2-(ethylaminomethyl)-4-(hydroxymethyl)-N-propan-2-yl-1-azetidinecarboxamide
[(1R)-7-methoxy-9-methyl-1-(4-oxanylmethyl)-1-spiro[2,3-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]yl]methanol
C22H31N3O3 (385.23652960000004)
(2S,3R)-1-[cyclopentyl(oxo)methyl]-2-(hydroxymethyl)-3-phenyl-N-propan-2-yl-1,6-diazaspiro[3.3]heptane-6-carboxamide
C22H31N3O3 (385.23652960000004)
[(2S,3R,4R)-1-(4-ethyl-1,3-thiazol-2-yl)-4-[(propan-2-ylamino)methyl]-3-[4-[(E)-prop-1-enyl]phenyl]azetidin-2-yl]methanol
(2S,3R,4R)-2-(acetamidomethyl)-3-[4-(1-cyclopentenyl)phenyl]-4-(hydroxymethyl)-N-propyl-1-azetidinecarboxamide
C22H31N3O3 (385.23652960000004)
[(1S)-7-methoxy-9-methyl-1-(4-oxanylmethyl)-1-spiro[2,3-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]yl]methanol
C22H31N3O3 (385.23652960000004)
1-[(1S)-1-(hydroxymethyl)-7-methoxy-9-methyl-1-spiro[2,3-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]yl]-1-butanone
C22H31N3O3 (385.23652960000004)
(2S,3S)-1-[cyclopentyl(oxo)methyl]-2-(hydroxymethyl)-3-phenyl-N-propan-2-yl-1,6-diazaspiro[3.3]heptane-6-carboxamide
C22H31N3O3 (385.23652960000004)
Methyl (1S,9R,10S,12S,15R)-13-ethenyl-10-hydroxy-18-(hydroxymethyl)-15-methyl-8-aza-15-azoniapentacyclo[10.5.1.01,9.02,7.09,15]octadeca-2,4,6-triene-18-carboxylate
O-[(9Z)-3-hydroxytetradec-9-enoyl]carnitine
An O-hydroxytetradecenoylcarnitine having (9Z)-3-hydroxytetradec-9-enoyl as the acyl substituent.
(8Z,11Z,14Z,17Z,20Z)-hexacosapentaenoate
A polyunsaturated fatty acid anion that is the conjugate base of (8Z,11Z,14Z,17Z,20Z)-hexacosapentaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.
(11Z,14Z,17Z,20Z,23Z)-hexacosapentaenoate
A hexacosapentaenoate that is the conjugate base of (11Z,14Z,17Z,20Z,23Z)-hexacosapentaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.
(2E)-15-[(3,6-dideoxy-alpha-L-arabino-hexopyranosyl)oxy]pentadec-2-enoate
(E,14R)-14-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxypentadec-2-enoate
(5S,6Z,8E,12S,14Z)-5,12,20,20,20-pentahydroxyicosa-6,8,14-trienoate
8-[3-hydroxy-6-methyl-5-[(E)-2-methylbut-2-enoyl]oxyoxan-2-yl]oxynonanoate
8-(2-[4-(2-Methoxyphenyl)-1-piperazinyl]ethyl)-8-azaspiro[4.5]decane-7,9-dione
C22H31N3O3 (385.23652960000004)
D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists
hexacosapentaenoate
A polyunsaturated fatty acid anion that is the conjugate base of hexacosapentaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.
O-(hydroxytetradecenoyl)carnitine
An O-acylcarnitine in which the acyl group specified is hydroxytetradecenoyl.
oscr#25(1-)
A hydroxy fatty acid ascaroside anion that is the conjugate base of oscr#25, obtained by deprotonation of the carboxy group; major species at pH 7.3.
CarE(14:1)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
NA-Gly 22:6(4Z,7Z,10Z,13Z,16Z,19Z)
C24H35NO3 (385.26168000000007)
ZT-12-037-01
ZT-12-037-01 is a STK19-targeted inhibitor, has a high-affinity interaction with STK19 protein and inhibits oncogenic NRAS-driven melanocyte malignant transformation. ZT-12-037-01 is an ATP-competitive inhibitor, inhibiting phosphorylation of NRAS (major isoform of Ras family) with an IC50 of 24 nM[1].
methyl (1r,3r,4r,14s)-19-hydroxy-18-(hydroxymethyl)-14-methyl-12-azahexacyclo[10.6.1.1¹,⁴.0¹⁰,¹⁸.0¹⁵,¹⁹.0⁷,²⁰]icosa-7(20),16-diene-3-carboxylate
C23H31NO4 (385.22529660000004)
2-(4,8-dimethylnona-3,7-dien-1-yl)-2-methyl-3h,4h,9h-pyrano[2,3-e]isoindole-3,5,7-triol
C23H31NO4 (385.22529660000004)
methyl 2-hydroxy-5,20-dimethyl-9-oxa-3-azaheptacyclo[9.8.1.1¹,¹⁴.0²,⁶.0³,¹⁰.0⁸,²⁰.0¹⁷,²¹]henicos-14(21)-ene-18-carboxylate
C23H31NO4 (385.22529660000004)
3-[2-(but-2-en-2-yl)-3,6,8-trimethyl-1,2,4a,5,6,7,8,8a-octahydronaphthalene-1-carbonyl]-5-methoxy-5-methylpyrrol-2-ol
C24H35NO3 (385.26168000000007)
methyl (1'r,5's,11'r,12'r)-6-ethyl-3'-methyl-9'-oxo-2,4-dihydro-3'-azaspiro[pyran-3,15'-tetracyclo[6.5.1.1¹,⁵.0¹¹,¹⁴]pentadecan]-8'(14')-ene-12'-carboxylate
C23H31NO4 (385.22529660000004)
methyl (1r,3r,4r,10s,14s,19r)-19-hydroxy-18-(hydroxymethyl)-14-methyl-12-azahexacyclo[10.6.1.1¹,⁴.0¹⁰,¹⁸.0¹⁵,¹⁹.0⁷,²⁰]icosa-7(20),16-diene-3-carboxylate
C23H31NO4 (385.22529660000004)
(2z,4e,7r,8s,9s,10r)-9-hydroxy-8,10-dimethyl-7-{[(2e)-3-phenylprop-2-enoyl]oxy}dodeca-2,4-dienimidic acid
C23H31NO4 (385.22529660000004)
(2r,2'r,4'as,6's,8'as)-2',5',5',8'a-tetramethyl-3,3',4',4'a,6,6',7',8'-octahydro-2'h-spiro[furo[2,3-e]isoindole-2,1'-naphthalene]-4,6',8-triol
C23H31NO4 (385.22529660000004)
2',5',5',8'a-tetramethyl-3,3',4',4'a,6,6',7',8'-octahydro-2'h-spiro[furo[2,3-e]isoindole-2,1'-naphthalene]-4,6',8-triol
C23H31NO4 (385.22529660000004)
(2r,2's,4'as,6'r,8'as)-2',5',5',8'a-tetramethyl-3,3',4',4'a,6,6',7',8'-octahydro-2'h-spiro[furo[2,3-e]isoindole-2,1'-naphthalene]-4,6',8-triol
C23H31NO4 (385.22529660000004)
5-{[(2e,6e)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]oxy}-3h-isoindole-1,4,6-triol
C23H31NO4 (385.22529660000004)
(1s,9r,10s,12s,13e,15s,18s)-13-ethylidene-10-hydroxy-18-(hydroxymethyl)-18-(methoxycarbonyl)-15-methyl-8,15-diazapentacyclo[10.5.1.0¹,⁹.0²,⁷.0⁹,¹⁵]octadeca-2,4,6-trien-15-ium
(3s,3ar,4s,6as,15ar)-1,12-dihydroxy-4,5,8-trimethyl-3-(2-methylpropyl)-3h,3ah,4h,6ah,9h,10h,11h,12h-cycloundeca[d]isoindol-15-one
C24H35NO3 (385.26168000000007)
(1s,13r,14s,17s,19s)-13,14,18,18-tetramethyl-2-oxa-6-azapentacyclo[11.8.0.0¹,¹⁷.0³,¹¹.0⁴,⁸]henicosa-3(11),4(8),6,9-tetraene-7,10,19-triol
C23H31NO4 (385.22529660000004)
(2r)-2-[(dihydroxycarbonimidoyl)methyl]-n-[(2s)-1-[(2s)-2-(hydroxymethyl)pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]heptanimidic acid
C19H35N3O5 (385.25765800000005)
(5r)-3-[(1s,2r,4ar,6r,8s,8as)-2-[(2e)-but-2-en-2-yl]-3,6,8-trimethyl-1,2,4a,5,6,7,8,8a-octahydronaphthalene-1-carbonyl]-5-methoxy-5-methylpyrrol-2-ol
C24H35NO3 (385.26168000000007)
13-(2h-1,3-benzodioxol-5-yl)-n-(2-methylpropyl)trideca-2,12-dienimidic acid
C24H35NO3 (385.26168000000007)
1-[(1s,3r,6s,8r,11s,12s,14r,15r,16r)-6-(dimethylamino)-14-hydroxy-12,16-dimethyl-7-methylidenepentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadecan-15-yl]ethanone
(3r,8r,11s,12s,14r,15s,16r)-14-hydroxy-7,7,12,16-tetramethyl-15-[(1s)-1-(methylamino)ethyl]pentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadec-4-en-6-one
2-[(2e,5e,7e,11e)-10-hydroxy-3,7,9,11-tetramethyltrideca-2,5,7,11-tetraen-1-yl]-6-methoxy-3-methylpyridin-4-ol
C24H35NO3 (385.26168000000007)
5-[(3,7,11-trimethyldodeca-2,6,10-trien-1-yl)oxy]-3h-isoindole-1,4,6-triol
C23H31NO4 (385.22529660000004)
3-[(2r,3r,5s,6r)-6-[(2r)-butan-2-yl]-3,5-dimethyloxan-2-yl]-4-hydroxy-1-methoxy-5-phenylpyridin-2-one
C23H31NO4 (385.22529660000004)
(2z,4e,7r,8r,9s,10r)-7-hydroxy-8,10-dimethyl-9-{[(2e)-3-phenylprop-2-enoyl]oxy}dodeca-2,4-dienimidic acid
C23H31NO4 (385.22529660000004)
methyl 8-hydroxy-2,6-dimethyl-4-oxa-9-azaheptacyclo[12.5.1.1³,⁷.0¹,⁸.0²,¹¹.0⁵,⁹.0¹⁷,²⁰]henicos-14(20)-ene-18-carboxylate
C23H31NO4 (385.22529660000004)
methyl (1r,2r,3r,5r,6s,10s,16r,17r)-2-(hydroxymethyl)-6-methyl-20-oxo-8-azahexacyclo[11.5.1.1¹,⁵.0²,¹⁰.0³,⁸.0¹⁶,¹⁹]icos-13(19)-ene-17-carboxylate
C23H31NO4 (385.22529660000004)
methyl 2-hydroxy-5,9-dimethyl-20-oxa-3-azaheptacyclo[11.5.2.1³,¹⁰.0¹,⁹.0²,⁶.0¹³,¹⁹.0¹⁶,¹⁹]henicos-16-ene-17-carboxylate
C23H31NO4 (385.22529660000004)
(3s,3ar,4s,6as,12s,15ar)-1,12-dihydroxy-4,5,8-trimethyl-3-(2-methylpropyl)-3h,3ah,4h,6ah,9h,10h,11h,12h-cycloundeca[d]isoindol-15-one
C24H35NO3 (385.26168000000007)
7-hydroxy-8,10-dimethyl-9-[(3-phenylprop-2-enoyl)oxy]dodeca-2,4-dienimidic acid
C23H31NO4 (385.22529660000004)
1,12-dihydroxy-4,5,8-trimethyl-3-(2-methylpropyl)-3h,3ah,4h,6ah,9h,10h,11h,12h-cycloundeca[d]isoindol-15-one
C24H35NO3 (385.26168000000007)
methyl (1s,2r,6r,9s,10s,13s,19r)-2-hydroxy-5,9-dimethyl-20-oxa-3-azaheptacyclo[11.5.2.1³,¹⁰.0¹,⁹.0²,⁶.0¹³,¹⁹.0¹⁶,¹⁹]henicos-16-ene-17-carboxylate
C23H31NO4 (385.22529660000004)
(2s,2'r,4'as,6'r,8'as)-2',5',5',8'a-tetramethyl-3,3',4',4'a,5,6',7',8'-octahydro-2'h-spiro[furo[2,3-f]isoindole-2,1'-naphthalene]-4,6',7-triol
C23H31NO4 (385.22529660000004)
(2e,4e,7r,8r,9s,10r)-7-hydroxy-8,10-dimethyl-9-{[(2e)-3-phenylprop-2-enoyl]oxy}dodeca-2,4-dienimidic acid
C23H31NO4 (385.22529660000004)
methyl (1r,10r,15r,18s,19r)-17,19-dihydroxy-14,18-dimethyl-12-azahexacyclo[10.6.1.1¹,⁴.0¹⁰,¹⁸.0¹⁵,¹⁹.0⁷,²⁰]icosa-3,7(20)-diene-3-carboxylate
C23H31NO4 (385.22529660000004)
n-[2-(4-{[3-(5,5-dimethyl-4-oxofuran-2-yl)but-2-en-1-yl]oxy}phenyl)ethyl]-3-methylbutanimidic acid
C23H31NO4 (385.22529660000004)
methyl (1r,2s,3r,5s,6s,7r,8r,11s,17r,18r)-8-hydroxy-2,6-dimethyl-4-oxa-9-azaheptacyclo[12.5.1.1³,⁷.0¹,⁸.0²,¹¹.0⁵,⁹.0¹⁷,²⁰]henicos-14(20)-ene-18-carboxylate
C23H31NO4 (385.22529660000004)
1-hydroxy-4,5,8-trimethyl-3-(2-methylpropyl)-3h,3ah,4h,6ah,9h,10h,11h,13h,14h-cycloundeca[d]isoindole-12,15-dione
C24H35NO3 (385.26168000000007)
(3s,3ar,4s,6as,12r,15ar)-1,12-dihydroxy-4,5,8-trimethyl-3-(2-methylpropyl)-3h,3ah,4h,6ah,9h,10h,11h,12h-cycloundeca[d]isoindol-15-one
C24H35NO3 (385.26168000000007)
(2e,4e,7r,8s,9s,10r)-9-hydroxy-8,10-dimethyl-7-{[(2e)-3-phenylprop-2-enoyl]oxy}dodeca-2,4-dienimidic acid
C23H31NO4 (385.22529660000004)
(5z)-3-[(1s,2r,4as,6r,8ar)-6-hydroxy-1,3,6-trimethyl-2-[(1e)-prop-1-en-1-yl]-2,4a,5,7,8,8a-hexahydronaphthalene-1-carbonyl]-5-ethylidenepyrrole-2,4-diol
C23H31NO4 (385.22529660000004)
9-hydroxy-8,10-dimethyl-7-[(3-phenylprop-2-enoyl)oxy]dodeca-2,4-dienimidic acid
C23H31NO4 (385.22529660000004)
(1s,2s,5r,7r,8r,11r,12s,18r)-12-methyl-6-methylidene-17-oxa-14-azahexacyclo[10.6.3.1⁵,⁸.0¹,¹¹.0²,⁸.0¹⁴,¹⁸]docosan-7-yl acetate
C24H35NO3 (385.26168000000007)
methyl 2-(hydroxymethyl)-6-methyl-20-oxo-8-azahexacyclo[11.5.1.1¹,⁵.0²,¹⁰.0³,⁸.0¹⁶,¹⁹]icos-13(19)-ene-17-carboxylate
C23H31NO4 (385.22529660000004)
methyl 19-hydroxy-18-(hydroxymethyl)-14-methyl-12-azahexacyclo[10.6.1.1¹,⁴.0¹⁰,¹⁸.0¹⁵,¹⁹.0⁷,²⁰]icosa-7(20),16-diene-3-carboxylate
C23H31NO4 (385.22529660000004)
methyl (1r,3r,4r,10s,14s,15r,18s,19r)-19-hydroxy-18-(hydroxymethyl)-14-methyl-12-azahexacyclo[10.6.1.1¹,⁴.0¹⁰,¹⁸.0¹⁵,¹⁹.0⁷,²⁰]icosa-7(20),16-diene-3-carboxylate
C23H31NO4 (385.22529660000004)
(2r)-2-({[(2r)-1-[(2r)-3-(dihydroxycarbonimidoyl)-2-(2-methylpropyl)propanoyl]pyrrolidin-2-yl](hydroxy)methylidene}amino)-3-methylbutanoic acid
13,14,18,18-tetramethyl-2-oxa-6-azapentacyclo[11.8.0.0¹,¹⁷.0³,¹¹.0⁴,⁸]henicosa-3(11),4(8),6,9-tetraene-7,10,19-triol
C23H31NO4 (385.22529660000004)
2',5',5',8'a-tetramethyl-3,3',4',4'a,6',7',8,8'-octahydro-2'h-spiro[furo[2,3-e]isoindole-2,1'-naphthalene]-4,6,6'-triol
C23H31NO4 (385.22529660000004)
(2r,2'r,4'as,6'r,8'as)-2',5',5',8'a-tetramethyl-3,3',4',4'a,6,6',7',8'-octahydro-2'h-spiro[furo[2,3-e]isoindole-2,1'-naphthalene]-4,6',8-triol
C23H31NO4 (385.22529660000004)
3-[3,5-dimethyl-6-(sec-butyl)oxan-2-yl]-4-hydroxy-1-methoxy-5-phenylpyridin-2-one
C23H31NO4 (385.22529660000004)
(2z,4e,7s,8r,9r,10s)-9-hydroxy-8,10-dimethyl-7-{[(2e)-3-phenylprop-2-enoyl]oxy}dodeca-2,4-dienimidic acid
C23H31NO4 (385.22529660000004)
methyl 4-(2-acetyl-4-oxoundec-1-en-1-yl)-6-(prop-1-en-1-yl)pyridine-3-carboxylate
C23H31NO4 (385.22529660000004)
3-[(1s,2r,4ar,6r,8s,8as)-2-[(2e)-but-2-en-2-yl]-3,6,8-trimethyl-1,2,4a,5,6,7,8,8a-octahydronaphthalene-1-carbonyl]-5-methoxy-5-methylpyrrol-2-ol
C24H35NO3 (385.26168000000007)
(2s,3s)-2-[(3e)-4,8-dimethylnona-3,7-dien-1-yl]-2-methyl-3h,4h,9h-pyrano[2,3-e]isoindole-3,5,7-triol
C23H31NO4 (385.22529660000004)
2',5',5',8'a-tetramethyl-3,3',4',4'a,5,6',7',8'-octahydro-2'h-spiro[furo[2,3-f]isoindole-2,1'-naphthalene]-4,6',7-triol
C23H31NO4 (385.22529660000004)
(2s,4e)-5-hydroxy-4-[(2s,4r,6e)-1-hydroxy-2,4,6-trimethylnon-6-en-1-ylidene]-2-[(4-hydroxyphenyl)methyl]-2h-pyrrol-3-one
C23H31NO4 (385.22529660000004)
(1s,3s,8r,11s,14r,15s,16r)-14-hydroxy-7,7,12,16-tetramethyl-15-[(1s)-1-(methylamino)ethyl]pentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadec-4-en-6-one
methyl (1r,2s,5s,6s,7r,8r,11s,17r,18r)-8-hydroxy-2,6-dimethyl-4-oxa-9-azaheptacyclo[12.5.1.1³,⁷.0¹,⁸.0²,¹¹.0⁵,⁹.0¹⁷,²⁰]henicos-14(20)-ene-18-carboxylate
C23H31NO4 (385.22529660000004)
(2s,3s)-2-(4,8-dimethylnona-3,7-dien-1-yl)-2-methyl-3h,4h,9h-pyrano[2,3-e]isoindole-3,5,7-triol
C23H31NO4 (385.22529660000004)
methyl (1r,3r,4r,10s,14s,15r,18r,19s)-19-hydroxy-18-(hydroxymethyl)-14-methyl-12-azahexacyclo[10.6.1.1¹,⁴.0¹⁰,¹⁸.0¹⁵,¹⁹.0⁷,²⁰]icosa-7(20),16-diene-3-carboxylate
C23H31NO4 (385.22529660000004)
(2r,2's,4'as,6'r,8'as)-2',5',5',8'a-tetramethyl-3,3',4',4'a,6',7',8,8'-octahydro-2'h-spiro[furo[2,3-e]isoindole-2,1'-naphthalene]-4,6,6'-triol
C23H31NO4 (385.22529660000004)
methyl (1'r,3s,5's,11'r,12'r)-6-isopropyl-3'-methyl-2,4-dihydro-3'-azaspiro[pyran-3,15'-tetracyclo[6.5.1.1¹,⁵.0¹¹,¹⁴]pentadecan]-8'(14')-ene-12'-carboxylate
C24H35NO3 (385.26168000000007)
(1r,2s,5s,11s,12r,14r,15s,16r,17r)-12,15-dihydroxy-5-methyl-13-methylidene-8-azaheptacyclo[8.6.2.2¹¹,¹⁴.0¹,⁹.0⁵,¹⁷.0⁶,⁸.0¹¹,¹⁶]icosan-2-yl acetate
C23H31NO4 (385.22529660000004)
(3s,3ar,4s,6as,15ar)-1-hydroxy-4,5,8-trimethyl-3-(2-methylpropyl)-3h,3ah,4h,6ah,9h,10h,11h,13h,14h-cycloundeca[d]isoindole-12,15-dione
C24H35NO3 (385.26168000000007)
(2e,12e)-13-(2h-1,3-benzodioxol-5-yl)-n-(2-methylpropyl)trideca-2,12-dienimidic acid
C24H35NO3 (385.26168000000007)
(2s)-2-({[(2s)-1-[(2r)-3-(dihydroxycarbonimidoyl)-2-(2-methylpropyl)propanoyl]pyrrolidin-2-yl](hydroxy)methylidene}amino)-3-methylbutanoic acid
methyl (1s,8r,10r,15r,18s,19r)-8,19-dihydroxy-14,18-dimethyl-12-azahexacyclo[10.6.1.1¹,⁴.0¹⁰,¹⁸.0¹⁵,¹⁹.0⁷,²⁰]icosa-3,7(20)-diene-3-carboxylate
C23H31NO4 (385.22529660000004)
methyl 4-[(1e)-2-acetyl-4-oxoundec-1-en-1-yl]-6-[(1e)-prop-1-en-1-yl]pyridine-3-carboxylate
C23H31NO4 (385.22529660000004)
12-methyl-6-methylidene-17-oxa-14-azahexacyclo[10.6.3.1⁵,⁸.0¹,¹¹.0²,⁸.0¹⁴,¹⁸]docosan-7-yl acetate
C24H35NO3 (385.26168000000007)
5-ethylidene-3-[6-hydroxy-1,3,6-trimethyl-2-(prop-1-en-1-yl)-2,4a,5,7,8,8a-hexahydronaphthalene-1-carbonyl]pyrrole-2,4-diol
C23H31NO4 (385.22529660000004)
(1s,9r,12r,18r)-13-ethylidene-10-hydroxy-18-(hydroxymethyl)-18-(methoxycarbonyl)-15-methyl-8,15-diazapentacyclo[10.5.1.0¹,⁹.0²,⁷.0⁹,¹⁵]octadeca-2,4,6-trien-15-ium
methyl (1s,2r,5s,6r,9s,10s,13r,19r)-2-hydroxy-5,9-dimethyl-20-oxa-3-azaheptacyclo[11.5.2.1³,¹⁰.0¹,⁹.0²,⁶.0¹³,¹⁹.0¹⁶,¹⁹]henicos-16-ene-17-carboxylate
C23H31NO4 (385.22529660000004)
n-[2-(4-{[(2e)-3-(5,5-dimethyl-4-oxofuran-2-yl)but-2-en-1-yl]oxy}phenyl)ethyl]-3-methylbutanimidic acid
C23H31NO4 (385.22529660000004)
(1s,3r,8r,11s,12s,14r,15s,16r)-14-hydroxy-7,7,12,16-tetramethyl-15-[(1s)-1-(methylamino)ethyl]pentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadec-4-en-6-one
(2s)-2-(n,3-dimethyl-2-oxopentanamido)-n-[2-(1h-indol-3-yl)ethyl]-3-methylbutanimidic acid
C22H31N3O3 (385.23652960000004)
(2z,4e,7s,8s,9r,10s)-7-hydroxy-8,10-dimethyl-9-{[(2e)-3-phenylprop-2-enoyl]oxy}dodeca-2,4-dienimidic acid
C23H31NO4 (385.22529660000004)
1-[6-(dimethylamino)-14-hydroxy-12,16-dimethyl-7-methylidenepentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadecan-15-yl]ethanone
5-hydroxy-4-(1-hydroxy-2,4,6-trimethylnon-6-en-1-ylidene)-2-[(4-hydroxyphenyl)methyl]-2h-pyrrol-3-one
C23H31NO4 (385.22529660000004)